SEC Comment Letter 0000000000-25-000700 to Biofrontera Inc. (BFRI)
Biofrontera Inc.
Date: Jan. 22, 2025 · CIK: 0001858685 · Accession: 0000000000-25-000700
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284371
Letter
January 22, 2025 Prof. Hermann Luebbert, Ph.D. Chairman and Chief Executive Officer Biofrontera Inc. 120 Presidential Way, Suite 330 Woburn, MA 01801 Re:Biofrontera Inc. Registration Statement on Form S-1 Filed January 17, 2025 File No. 333-284371 Dear Prof. Hermann Luebbert Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Stephen E. Older, Esq.
Show Raw Text
January 22, 2025
Prof. Hermann Luebbert, Ph.D.
Chairman and Chief Executive Officer
Biofrontera Inc.
120 Presidential Way, Suite 330
Woburn, MA 01801
Re:Biofrontera Inc.
Registration Statement on Form S-1
Filed January 17, 2025
File No. 333-284371
Dear Prof. Hermann Luebbert Ph.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Stephen E. Older, Esq.